Vanda Pharmaceuticals (VNDA) Projected to Post Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $52.25 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $4.62 on Tuesday. The stock’s 50 day moving average price is $4.64 and its 200-day moving average price is $4.89. Vanda Pharmaceuticals has a twelve month low of $3.71 and a twelve month high of $6.75.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

VNDA has been the topic of several research analyst reports. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 4th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.